Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

This study in patients with ERBB2 (HER2)-positive breast cancer (n=202) found trastuzumab emtansine was associated with a similar pathologic complete response rate to standard therapy with docetaxel, trastuzumab, and pertuzumab (43.9% v 45.5%; p=0.82).

Source:

JAMA Oncology